Abstract
Blockade of the mitogen-activated protein (MAP) kinase pathway suppresses growth of colon cancer in vivo. Here we demonstrate a direct link between the extracellular signal-regulated kinase ERK2 and the growth-promoting cell adhesion molecule, integrin αvβ6, in colon cancer cells. Down-regulation of β6 integrin subunit expression inhibits tumour growth in vivo and MAP kinase activity in response to serum stimulation. In αvβ6-expressing cells ERK2 is bound only to the β6 subunit. The increase in cytosolic MAP kinase activity upon epidermal growth factor stimulation is all accounted for by β6-bound ERK. Deletion of the ERK2 binding site on the β6 cytoplasmic domain inhibits tumour growth and leads to an association between ERK and the β5 subunit. The physical interaction between integrin αvβ6 and ERK2 defines a novel paradigm of integrin-mediated signalling and provides a therapeutic target for cancer treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Agrez MV, Bates RC, Mitchell D, Wilson N, Ferguson N, Anseline P, Sheppard D . 1996 Br. J. Cancer 73: 887–892
Agrez MV, Chen A, Cone RI, Pytela R, Sheppard D . 1994 J. Cell Biol. 127: 547–556
Agrez MV, Gu X, Turton J, Meldrum C, Niu J, Antalis T, Howard EW . 1999 Int. J. Cancer 81: 90–97
Aplin AE, Stewart SA, Assoian RK, Juliano RL . 2001 J. Cell Biol. 153: 271–281
Arihiro K, Kaneko M, Fujii S, Inai K, Yokosaki Y . 2000 Breast Cancer 7: 19–26
Bonni A, Brunet A, West AE, Batta SR, Takasu MA, Greenberg ME . 1999 Science 286: 1358–1362
Boulton TG, Nye SH, Robbins DJ . 1991 Cell 65: 663–675
Breuss JM, Gallo J, De Lisser HM, Klimanskaya IV, Folkesson HG, Pittet JF, Nishimura SL, Aldape K, Landers DV, Carrenter W, Gillet N, Sheppard D, Mathay M, Albeda SM, Kramer RH, Pytela R . 1995 J. Cell Sci. 108: 2241–2251
Clark EA, Brugge JS . 1995 Science 268: 233–239
Cone RI, Weinacker A, Chen A, Sheppard D . 1994 Cell Adhes. Comm. 2: 101–113
Davis RJ . 1993 J. Biol. Chem. 268: 14553–14556
Duesbery NS, Webb CP, Vande Woude GF . 1999 Nature Med. 5: 736–737
Fincham VJ, James M, Frame MC, Winder SJ . 2000 EMBO J. 19: 2911–2923
Giancotti FG, Ruoslahti E . 1999 Science 285: 1028–1032
Hamidi S, Salo T, Kainulainen T, Epstein J, Lerner K, Larjava H . 2000 Br. J. Cancer 82: 1433–1440
Hewitt RE, Leach IH, Powe DE, Clark IM, Cawston TE, Turner DR . 1991 Int. J. Cancer 49: 666–672
Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J, Kohno M . 1999 Oncogene 18: 813–822
Hynes RO . 1992 Cell 69: 11–25
Johansson N, Ala-aho R, Uitto V, Grenman R, Fusenig NE, Lopez-Otin C, Kahari VM . 2000 J. Cell Sci. 113: 227–235
Kerkhoff E, Houben R, Loffler S, Troppmair J, Lee JE, Rapp UR . 1998 Oncogene 16: 211–216
Lavoie JN, L'Allemain G, Brunet A, Muller R, Pouyssegur J . 1996 J. Biol. Chem. 271: 20608–20616
Licato LL, Keku TO, Wurzelmann JL, Murray SC, Woosley JT, Sandler RS, Brenner DA . 1997 Gastroenterology 113: 1589–1598
Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, Vande-Woude GF, Ahn NG . 1994 Science 265: 966–970
McCawley LJ, Li S, Wattenberg EV, Hudson LG . 1999 J. Biol. Chem. 274: 4347–4353
Niu J, Gu X, Ahmed N, Andrews S, Turton J, Bates R, Agrez M . 2001 Int. J. Cancer 92: 40–48
Partik G, Hochegger K, Schorkhuber M, Marian B . 1999 J. Cancer Res. Clin. Oncol. 125: 379–388
Payne DM, Rossomando AJ, Martino P, Erickson AK, Her JH, Shabanowitz J, Hunt DF, Weber MJ, Sturgill TW . 1991 EMBO J. 10: 885–892
Reszka AA, Seger R, Diltz CD, Krebs EG, Fischer EH . 1995 Proc. Natl. Acad. Sci. USA 92: 8881–8885
Schlaepfer DD, Hunter T . 1997 J. Biol. Chem. 272: 13189–13195
Sebolt-Leopold JS, Dudley DT, Herrera R . 1999 Nature Med. 5: 810–816
Sharrocks AD, Yang S-H, Galanis A . 2000 TIBS 25: 448–453
Sheppard D, Rozzo C, Starr L, Quaranta V, Erle DJ, Pytela R . 1990 J. Biol. Chem. 265: 11502–11507
Thomas GJ, Jones J, Speight PM . 1997 Oral Oncol. 33: 381–388
Weinacker A, Chen A, Agrez M, Cone RI, Nishimura S, Wayner E, Pytela R, Sheppard D . 1994 J. Biol. Chem. 269: 6940–6948
Wolf I, Rubinfeld H, Yoon S, Marmor G, Hanoch T, Seger R . 2001 J. Biol. Chem. 276: 24490–24497
Xing J, Ginty DD, Greenberg ME . 1996 Science 273: 959–963
Zeigler ME, Chi Y, Schmidt T, Varani J . 1999 J. Cell Physiol. 180: 271–284
Acknowledgements
We thank J Turton for assistance with preparation of the antisense β6. This work was supported jointly by grants from the New South Wales State Cancer Council, the National Health and Medical Research Council of Australia, The University of Newcastle Research Associates (TUNRA) Ltd. and the New South Wales Department of Health. MV Agrez was supported by a John Mitchell Crouch Fellowship from the Royal Australasian College of Surgeons. DJ Dorahy is and N Ahmed was a Brawn Postdoctoral Fellow, The University of Newcastle, New South Wales.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ahmed, N., Niu, J., Dorahy, D. et al. Direct integrin αvβ6-ERK binding: implications for tumour growth. Oncogene 21, 1370–1380 (2002). https://doi.org/10.1038/sj.onc.1205286
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205286
Keywords
This article is cited by
-
Gene isoforms as expression-based biomarkers predictive of drug response in vitro
Nature Communications (2017)
-
Integrin β6 serves as an immunohistochemical marker for lymph node metastasis and promotes cell invasiveness in cholangiocarcinoma
Scientific Reports (2016)
-
Norcantharidin Suppresses Colon Cancer Cell Epithelial-Mesenchymal Transition by Inhibiting the αvβ6-ERK-Ets1 Signaling Pathway
Scientific Reports (2016)
-
Integrin β6 acts as an unfavorable prognostic indicator and promotes cellular malignant behaviors via ERK-ETS1 pathway in pancreatic ductal adenocarcinoma (PDAC)
Tumor Biology (2016)
-
Integrin β6 can be translationally regulated by eukaryotic initiation factor 4E: Contributing to colonic tumor malignancy
Tumor Biology (2015)